

آشنایی با پایگاه داده Pubmed



فاطمه صادقی غیاثی
مرکز پزشکی مبتنی بر شواهد



National Library of Medicine
National Center for Biotechnology Information

Log in

PubMed.gov

Search PubMed

Search

Advanced

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Feedback

سوال

آیا واکسن کرونا در پیشگیری از بیماری کووید ۱۹
مؤثر است؟

سوال

آیا واکسن کرونا در پیشگیری از بیماری کووید ۱۹
مؤثر است؟

PICO

P (Problem/Patient): Covid-19 ; coronavirus disease 2019 ; SARS-CoV-2 ;


I (Intervention): COVID-19 vaccine; vaccination;

C (Comparison):


O (Outcome): Prevention; immunity;

روش اول

عملگرهای بولین



روش اول



The image shows the PubMed.gov website interface. At the top left is the NIH logo and the text "National Library of Medicine" and "National Center for Biotechnology Information". At the top right is a "Log in" button. The PubMed.gov logo is prominently displayed in the center. Below the logo is a search bar containing the text "covid 19 AND vaccination AND prevention". This search bar is highlighted with an orange oval. To the right of the search bar is a green "Search" button. Below the search bar, the word "Advanced" is visible. At the bottom of the page, there is a paragraph of text: "PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites."

NIH National Library of Medicine
National Center for Biotechnology Information

Log in

PubMed.gov

covid 19 AND vaccination AND prevention

Advanced

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

covid-19 AND vaccination AND prevention



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Save

Email

Send to


Sorted by: Best match

Display options

MY NCBI FILTERS

2,991 results

RESULTS BY YEAR



TEXT AVAILABILITY

☐ Abstract



COVID-19: Transmission, prevention, and potential therapeutic opportunities.

1

Lotfi M, Hamblin MR, Rezaei N.

Cite

Clin Chim Acta. 2020 Sep;508:254-266. doi: 10.1016/j.cca.2020.05.044. Epub 2020 May 29.

PMID: 32474009 [Free PMC article.](#) [Review.](#)

Share

The novel **coronavirus** disease (**COVID-19**) pandemic, caused by **severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)**, remains a global challenge. ...In this review, current therapeutic option ...



COVID-19 and the immune system.

2

Paces J, Strizova Z, Smrz D, Cerny J.

Cite

Physiol Res. 2020 Jul 16;69(3):379-388. doi: 10.33549/physiolres.934492. Epub 2020 May 29.

PMID: 32469225 [Free article.](#) [Review.](#)

Share

covid-19 and vaccine



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Save

Email

Send to

Sorted by: Best match

Display options

MY NCBI FILTERS

6,709 results

RESULTS BY YEAR



TEXT AVAILABILITY

☐ Abstract

☐ Free full text



A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.

1

Sharma O, Sultan AA, Ding H, Trigg CR.

Cite

Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.

Share

PMID: 33163000 [Free PMC article.](#) [Review.](#)

A novel **coronavirus**, which has been designated as **severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)**, was first detected in December **2019** in Wuhan China and causes the highly infectious disease ...



Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

2

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED,


Cite

Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr,

Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU,

روش دوم

عملگرهای بولین



PICO


Truncations: * ; ? ;

- **Vaccin***: vaccine; vaccination; vaccines; ...

Quotation mark: “ ” ; ‘ ’

- “coronavirus disease 2019”

روش دوم



The image shows the PubMed.gov website interface. At the top left is the PubMed.gov logo. Below it is a search bar containing the query: "(covid-19 OR "coronavirus disease 2019" OR SARS-CoV-2) AND (vaccine OR vaccination OR immunity)". To the right of the search bar is a green button labeled "Search". Below the search bar, the word "Advanced" is visible. At the bottom, a paragraph states: "PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites."

PubMed.gov

(covid-19 OR "coronavirus disease 2019" OR SARS-CoV-2) AND (vaccine OR vaccination OR immunity)

Search

Advanced

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Save

Email

Send to

Sorted by: Best match

Display options

MY NCBI FILTERS



12,690 results

RESULTS BY YEAR



SARS-CoV-2 causing pneumonia-associated **respiratory** disorder (**COVID-19**): diagnostic and proposed therapeutic options.

1

Cite

Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS.

Share

Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026. doi: 10.26355/eurev_202004_20871.

PMID: 32329877

Free article.

Review.

SARS-CoV-2 is responsible for the outbreak of **severe respiratory** illness (**COVID-19**) in Wuhan City, China and is now spreading rapidly throughout the world. ...Lastly, potentials candidates for the **vaccines** against **SARS** ...



Current Status of Epidemiology, Diagnosis, Therapeutics, and **Vaccines** for Novel **Coronavirus Disease 2019 (COVID-19)**.

2

Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SI

TEXT AVAILABILITY



Abstract

<https://www.ncbi.nlm.nih.gov>

روش سوم (Advanced Search)

روش سوم



Advanced Search

 **National Library of Medicine**
National Center for Biotechnology Information

PubMed Advanced Search Builder


[User Guide](#)

Add terms to the query box

All Fields

Enter a search term

ADD

Show Index

Query box

Enter / edit your search query here

Search

History and Search Details

Download

Delete

nlm.nih.gov

Search **Actions** **Details** **Query**

Results **Time**

Add terms to the query box

All Fields

Pharmacological Action

Publication Type

Publisher

Secondary Source ID

Subject - Personal Name

Supplementary Concept

Text Word

Title

Title/Abstract

Transliterated Title

Volume

Enter a search term

ADD

Add with AND

Add with OR

Add with NOT

انتخاب فیلد جستجوی کلیدواژه

انتخاب یکی از عملگرهای بولین برای ترکیب کلیدواژه ها

you use PubMed your recent searches will appear here.

Add terms to the query box

All Fields

Enter a search term

ADD

Show Index

جستجو و نمایش نتایج جستجو

Query box

Enter / edit your search query here

Search

Add to History

Query box

Enter / edit your search query here

Add to History

اضافه کردن استراتژی و نتایج جستجو
در باکس history

Add terms to the query box

All Fields

Enter a search term

ADD

[Show Index](#)

Query box

Enter / edit your search query here

Search

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#13	...	>	Search: (covid-19 OR "coronavirus disease 2019" OR SARS-CoV-2) AND (vaccine OR vaccination OR immunity)	12,690	02:23:49
#6	...	>	Search: covid 19 AND vaccination AND prevention	2,991	02:22:15
#9	...	>	Search: covid 19 AND vaccination	6,709	02:03:03

Search	Actions	Details	Query	Results	Time
#13	...	▼	Search: (covid-19 OR "coronavirus disease 2019" OR SARS-CoV-2) AND (vaccine OR vaccination OR immunity) ("covid 19"[All Fields] OR "covid 19"[MeSH Terms] OR "covid 19 vaccines"[All Fields] OR "covid 19 vaccines"[MeSH Terms] OR "covid 19 serotherapy"[All Fields] OR "covid 19 serotherapy"[Supplementary Concept] OR "covid 19 nucleic acid testing"[All Fields] OR "covid 19 nucleic acid testing"[MeSH Terms] OR "covid 19 serological testing"[All Fields] OR "covid 19 serological testing"[MeSH Terms] OR "covid 19 testing"[All Fields] OR "covid 19 testing"[MeSH Terms] OR "sars cov 2"[All Fields] OR "sars cov 2"[MeSH Terms] OR "severe acute respiratory syndrome coronavirus 2"[All Fields] OR "ncov"[All Fields] OR "2019 ncov"[All Fields] OR (("coronavirus"[MeSH Terms] OR "coronavirus"[All Fields] OR "cov"[All Fields]) AND 2019/11/01:3000 /12/31[Date - Publication]) OR "coronavirus disease 2019"[All Fields] OR ("sars cov 2"[MeSH Terms] OR "sars cov 2"[All Fields] OR "sars cov 2"[All Fields])) AND ("vaccin"[Supplementary Concept] OR "vaccin"[All Fields] OR "vaccination"[MeSH Terms] OR "vaccination"[All Fields] OR "vaccinable"[All Fields] OR "vaccinal"[All Fields] OR "vaccinate"[All Fields] OR "vaccinated"[All Fields] OR "vaccinates"[All Fields] OR "vaccinating"[All Fields] OR "vaccinations"[All Fields] OR "vaccination s"[All Fields] OR "vaccinator"[All Fields] OR "vaccinators"[All Fields] OR "vaccine s"[All Fields] OR "vaccined"[All Fields] OR "vaccines"[MeSH Terms] OR "vaccines"[All Fields] OR "vaccine"[All Fields] OR "vaccins"[All Fields] OR ("vaccin"[Supplementary Concept] OR "vaccin"[All Fields] OR "vaccination"[MeSH Terms] OR "vaccination"[All Fields] OR "vaccinable"[All Fields] OR "vaccinal"[All Fields] OR "vaccinate"[All Fields] OR "vaccinated"[All Fields] OR "vaccinates"[All Fields] OR "vaccinating"[All	12,690	02:23:49

جزئیات استراتژی جستجو در
 باکس history

Add terms to the query box

Title/Abstract



Enter a search term



AND

[Show Index](#)

Query box

(covid-19[Title/Abstract]) AND (vaccin*[Title/Abstract])



Add to History



History and Search Details



Download



Delete


Search	Actions	Details	Query	Results	Time
#16	...	Add with AND	covid-19[Title/Abstract]) AND (vaccin*[Title/Abstract])	4,631	02:29:11
#13	...	Add with OR	covid-19 OR "coronavirus disease 2019" OR SARS-CoV-2)	12,690	02:23:49
		Add with NOT	accine OR vaccination OR immunity)		
#6	...	Delete	covid 19 AND vaccination AND prevention	2,991	02:22:15
#9	...	Create alert	covid 19 AND vaccination	6,709	02:03:03

نتایج جستجو

[Save](#)[Email](#)[Send to](#)[Sorted by: Best match](#)[Display options](#)[MY NCBI FILTERS](#)

4,631 results

RESULTS BY YEAR



TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE

- ☐ Associated data

ARTICLE TYPE



The cytokine storm and COVID-19.

1

Hu B, Huang S, Yin L.

Cite

J Med Virol. 2020 Jun 27;10.1002/jmv.26232. doi: 10.1002/jmv.26232. Online ahead of print.

Share

PMID: 32592501 [Free PMC article.](#) [Review.](#)

A growing body of clinical data suggests that a cytokine storm is associated with **COVID-19** severity and is also a crucial cause of death from **COVID-19**. In the absence of antivirals and **vaccines** for **COVID-19**, there is an urgent need ...



A compendium answering 150 questions on COVID-19 and SARS-CoV-2.

2

Riggioni C, Comberiati P, Giovannini M, Agache I, Akdis M, Alves-Correia M, Antó JM, Arcolaci A, Azkur AK, Azkur D, Beken B, Boccabella C, Bousquet J, Breiteneder H, Carvalho D, De Las Vecillas L, Diamant Z, Eguiluz-Gracia I, Eiwegger T, Eyerich S, Fokkens W, Gao YD, Hannachi F, Johnston SL, Jutel M, Karavelia A, Klimek L, Moya B, Nadeau KC, O'Hehir R, O'Mahony L, Pfaar O, Sanak M, Schwarze J, Sokolowska M, Torres MJ, van de Veen W, van Zelm MC, Wang Y, Zhang L, Jiménez-Saiz R, Akdis CA.

Cite

Allergy. 2020 Oct;75(10):2503-2541. doi: 10.1111/all.14449. Epub 2020 Jul 20.

Share

PMID: 32535955 [Free PMC article.](#) [Review.](#)

The epidemiologic features of **COVID-19** are distinctive and have changed throughout the pandemic. ...However, basic and clinical research on **COVID-19**-related topics should be based on

833 results

Save citations to file

Selection: All results on this page

Format: Summary (text)

Summary (text)

PubMed

PMID

Abstract (text)

CSV

833 results

Save

Email

Send to

Sorted by: Best match

Display options

833 results

Email citations


Subject: (covid-19 or coronavirus 2019 or SARS-Cov-2) and - PubMed

To:

Selection: **All results on this page**

Format: **Summary**

☐ I'm not a robot



Send email

Cancel

Save Email Send to

Sorted by: Best match

Display options

833 results

Save Email Send to

Sorted by: Best

Create

- Clipboard
- My Bibliography
- Collections
- Citation manager

citation management software

Selection

page

Cancel

Create a file for external citation management software

Selection:

All results

Create file

Cancel

Save

Email

Send to

Sorted by: Best match

Display options

833 results

Sorted by: Best match

Display options

DISPLAY OPTIONS

Format

Summary



Sort by

Summary

Abstract

PubMed


Per page

PMID

Show snippets



RESULTS BY YEAR



TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE

- ☐ Associated data

ARTICLE TYPE

- ☐ Books and Documents
- ☐ Clinical Trial
- ☐ Meta-Analysis

☐ 1

Review

> [Theranostics](#). 2020 Jun 19;10(17):7821-7835. doi: 10.7150/thno.47987. eCollection 2020.

COVID-19: Progress in diagnostics, therapy and vaccination

Xue Liu¹, Chao Liu², Gang Liu², Wenxin Luo¹, Ningshao Xia¹

Affiliations + expand


PMID: 32685022 PMCID: [PMC7359073](#) DOI: [10.7150/thno.47987](#)[Free PMC article](#)

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently become a pandemic. As the sudden emergence and rapid spread of SARS-CoV-2 is endangering global health and the economy, the development of strategies to contain the virus's spread are urgently needed. At present, various diagnostic kits to test for SARS-CoV-2 are available for use to initiate appropriate treatment faster and to limit further spread of the virus. Several drugs have demonstrated *in vitro* activity against SARS-CoV-2 or potential clinical benefits. In addition, institutions and companies worldwide are working tirelessly to develop treatments and vaccines against COVID-19. However, no drug or vaccine has yet been specifically approved for COVID-19. Given the

[Back to Top](#)

RESULTS BY YEAR



فیلترها

TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE

- ☐ Associated data

ARTICLE TYPE

- ☐ Books and Documents
- ☐ Clinical Trial
- ☐ Meta-Analysis
- ☐ Randomized Controlled Trial
- ☐ Review
- ☐ Systematic Review

Additional filters

Reset all filters

فیلترها

Additional filters

Reset all filters

ARTICLE TYPE

SPECIES

LANGUAGE

SEX

SUBJECT

JOURNAL

AGE

- | | |
|--|--|
| ☐ Address | ☐ Journal Article |
| ☐ Autobiography | ☐ Lecture |
| ☐ Bibliography | ☐ Legal Case |
| ☐ Biography | ☐ Legislation |
| ☐ Case Reports | ☐ Letter |
| ☐ Classical Article | ☐ Multicenter Study |
| ☐ Clinical Conference | ☐ News |
| ☐ Clinical Study | ☐ Newspaper Article |
| ☐ Clinical Trial Protocol | ☐ Observational Study |
| ☐ Clinical Trial, Phase I | ☐ Observational Study, Veterinary |

Cancel

Show

Review > Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.

Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design

Paul Barone¹, Robert A DeSimone¹

Affiliations + expand

PMID: 32374891 PMCID: PMC7267607 DOI: 10.1111/trf.15843

[Free PMC article](#)

Abstract

Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.

FULL TEXT LINKS



ACTIONS

“ Cite

☆ Favorites

SHARE



PAGE NAVIGATION

< Title & authors

Abstract

Conflict of interest statement

NEXT RESULT
5 of 833

Review > Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.

Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design

Paul Barone¹, Robert A DeSimone¹

Affiliations + expand

PMID: 32374891 PMCID: PMC7267607 DOI: 10.1111/trf.15843

Free PMC article

Abstract

Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.

FULL TEXT LINKS



ACTIONS



SHARE



PAGE NAVIGATION

< Title & authors

Abstract

Conflict of interest statement

NEXT RESULT
5 of 833

Cite

Considerations for clinical trial

CITATION TEXT

Barone, P., & DeSimone, R. A. (2020).
Convalescent plasma to treat coronavirus
disease 2019 (COVID-19): considerations for
clinical trial design. *Transfusion*, 60(6), 1123–
1127. <https://doi.org/10.1111/trf.15843>

 Copy  Download .nbib Format: APA 

07
ma
ede
ess, and for severe illness. Previous studies of convalescent

Page Navigation

Supplementary concepts

- > COVID-19
- > severe acute respiratory syndrome coronavirus

Related information

MedGen

LinkOut – more resources

Full Text Sources

Europe PubMed Central
Ovid Technologies, Inc.
PubMed Central
Wiley

Medical

MedlinePlus Health Information

PAGE NAVIGATION

Title & authors

< Abstract

Conflict of interest
statement

Similar articles

Cited by

References

Publication types


MeSH terms

Substances

Supplementary
concepts

Related information

LinkOut - more
resources



MeSH terms

- › Antibodies, Viral / blood*
- › Betacoronavirus / immunology*
- › Blood Component Transfusion / methods*
- › Clinical Trials as Topic / methods*
- › Convalescence*
- › Coronavirus Infections / immunology
- › Coronavirus Infections / therapy*
- › Coronavirus Infections / virology
- › Humans
- › Pandemics
- › Plasma / immunology*
- › Pneumonia, Viral / immunology
- › Pneumonia, Viral / therapy*
- › Pneumonia, Viral / virology
- › Research Design

Substances

- › Antibodies, Viral

PAGE NAVIGATION

Title & authors

◀ Abstract

Conflict of interest
statement

Similar articles

Cited by

References

Publication types


MeSH terms

Substances

Supplementary
concepts

Related information

LinkOut - more
resources



MeSH Database

[Search](#)[Advanced](#)

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.



Learn

[About PubMed](#)
[FAQs & User Guide](#)
[Finding Full Text](#)



Find

[Advanced Search](#)
[Clinical Queries](#)
[Single Citation Matcher](#)



Download

[E-utilities API](#)
[FTP](#)
[Batch Citation Matcher](#)



Explore

[MeSH Database](#)
[Journals](#)
[Legacy PubMed \(available until at least 10/31/2020\)](#)

MeSH

MeSH ▾


[Limits](#) [Advanced](#)

Search

[Help](#)



COVID-19 is an emerging, rapidly evolving situation.
 Get the latest public health information from CDC: <https://www.coronavirus.gov>.
 Get the latest research from NIH: <https://www.nih.gov/coronavirus>.
 Find NCBI SARS-CoV-2 literature, sequence, and clinical content: <https://www.ncbi.nlm.nih.gov/sars-cov-2/>.



MeSH

MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.

Using MeSH

[Help](#)

[Tutorials](#)

More Resources

[E-Utilities](#)

[NLM MeSH Homepage](#)



COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: <https://www.coronavirus.gov>.

Get the latest research from NIH: <https://www.nih.gov/coronavirus>.

Find NCBI SARS-CoV-2 literature, sequence, and clinical content: <https://www.ncbi.nlm.nih.gov/sars-cov-2/>.

Summary ▾ 20 per page ▾

Send to: ▾

Search results

Items: 1 to 20 of 72

<< First < Prev Page 1 of 4 Next > Last >>

☐ [Coronavirus](#)

1. A member of CORONAVIRIDAE which causes respiratory or gastrointestinal disease in a variety of vertebrates.
Year introduced: 1994

☐ [Middle East Respiratory Syndrome Coronavirus](#)

2. A **coronavirus** first reported in the summer of 2012 in a pneumonia patient in SAUDI ARABIA. It is related to SARS VIRUS. MERS-CoV has an estimated incubation period of 12 days and symptoms include renal failure and severe acute pneumonia with often fatal outcome.
Year introduced: 2015

☐ [Spike Glycoprotein, Coronavirus](#)

3. A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion.
Year introduced: 2014

PubMed Search Builder

Add to search builder AND ▾

Search PubMed

You Tutorial

Find related data

Database:

Find items

Search details

"coronavirus"[MeSH Terms] OR
coronavirus[Text Word]

Summary ▾ 20 per page ▾

Send to: ▾

Search results

Items: 1 to 20 of 31

<< First < Prev Page 1 of 2 Next > Last >>

☐ [COVID-19](#)

1. A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathies often correlating with **COVID-19** severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with **COVID-19** (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus **SARS-CoV-2** in the genus BETACORONAVIRUS is the causative agent.

Year introduced: 2021(2020)

☐ [SARS-CoV-2](#)

2. A species of BETACORONAVIRUS causing atypical respiratory disease (**COVID-19**) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.

Year introduced: 2021(2020)

PubMed Search Builder

[Add to search builder](#)

AND ▾

[Search PubMed](#)[YouTube](#) [Tutorial](#)

Find related data

Database: [Select](#) ▾[Find items](#)

Search details

"sars-cov-2"[MeSH Terms] OR
"covid-19"[MeSH Terms] OR
covid[Text Word]